問卷

TPIDB > Search Result

Search Result

篩選

List

1000Cases

2021-12-04 - 2024-09-30

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-10-31 - 2023-10-05

Phase II

Completed
A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
  • Condition/Disease

    Systemic Lupus Erythematosus(SLE)

  • Test Drug

    PF-06700841

Participate Sites
8Sites

Recruiting8Sites

2026-02-28 - 2031-02-21

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-03-20 - 2030-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-11-12 - 2030-12-19

Phase III

Active
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjogren’s Disease (SjD)
  • Condition/Disease

    Moderate to Severe Sjogren’s Disease (SjD)

  • Test Drug

    injective

Participate Sites
7Sites

Recruiting7Sites

2025-10-15 - 2031-11-14

Phase III

Not yet recruiting
A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants with Acute Suicidal Ideation or Behavior
  • Condition/Disease

    Major Depressive Disorder in Adolescent Participants with Acute Suicidal Ideation or Behavior

  • Test Drug

    nasal spray

Participate Sites
5Sites

Recruiting5Sites

2024-03-01 - 2028-06-30

Phase I/II

Active
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Condition/Disease

    Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Test Drug

    Amivantamab Paclitaxel Pembrolizumab Carboplatin

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2029-12-31

Phase III

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Naive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Condition/Disease

    Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Test Drug

    Subcutaneous injection Injection Injection Injection Injection

Participate Sites
7Sites

Recruiting7Sites

2025-09-01 - 2029-12-31

Phase III

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
7Sites

Recruiting7Sites

2024-12-20 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites